The Effect of Specialized Cancer Treatment Centers on Treatment Efficacy in Hodgkin's Lymphoma

Overview

Journal Dtsch Arztebl Int

Specialties General Medicine
Public Health

Date 2013 Feb 2

PMID 23372613

Citations 4

Authors

Beate Klimm

Corinne Brillant

Nicole Skoetz

Horst Muller

Andreas Engert

Peter Borchmann

Affiliations

Soon will be listed here.

Abstract

Background: The presumed benefits of centralization and minimum case numbers often guide health-policy decisions, but these benefits remain inadequately documented, particularly in oncology. In this study, we aim to measure the effect of the type of treatment center and/or the number of patients treated in it on the outcome of patients with Hodgkin's lymphoma.

Methods: From 1988 to 2002, 8121 patients with newly diagnosed Hodgkin's lymphoma were treated in Germany in multicenter randomized and controlled trials (RCTs) of the German Hodgkin Study Group (GHSG). Center-related effects on progression-free survival (PFS) were assessed univariately with Kaplan-Meier plots and log-rank tests, as well as with a multivariate Cox regression model.

Results: The 500 participating centers in Germany included 52 university hospitals, 304 non-university hospitals, and 144 medical practices specializing in hematology and oncology. No significant differences in PFS were found between patients from centers with high or low case numbers (5-year-PFS: 78.7% and 78.6% for centers with fewer than 50 and more than 50 patients, respectively) or from different types of centers [5-year-PFS: university hospital, 77.7%; non-university hospital, 79.4%; practice, 79.8%]. Even after statistical controls for the effect of other known and unknown prognostic factors and validation in further datasets, no center effects were found.

Conclusions: The type of center and the minimum number of patients treated in a center have no impact on the treatment outcome of patients with Hodgkin's lymphoma in Germany. In all GHSG centers, regardless of type, the quality standards for successful treatment are apparently met on all levels of patient care.

Citing Articles

Motherhood after cancer: fertility and utilisation of fertility-preservation methods.

Goeckenjan M, Freis A, Glass K, Schaar J, Trinkaus I, Torka S Arch Gynecol Obstet. 2020; 301(6):1579-1588.

PMID: 32377787 PMC: 7246243. DOI: 10.1007/s00404-020-05563-w.

Impact of Provider Volume on Outcomes of Patients With Hodgkin Lymphoma.

Ireland C, Wiedower E, Mirza M, Crawley M, Tran A, Yaghmour G World J Oncol. 2018; 9(2):46-49.

PMID: 29760832 PMC: 5942207. DOI: 10.14740/wjon1093w.

Achieving minimum caseload requirements: an analysis of hospital quality control reports from 2004-2010.

de Cruppe W, Malik M, Geraedts M Dtsch Arztebl Int. 2014; 111(33-34):549-55.

PMID: 25220064 PMC: 4165182. DOI: 10.3238/arztebl.2014.0549.

[Quality assurance, certification and the new Institute for Quality in Medicine].

Hakenberg O, Schroeder A Urologe A. 2014; 53(8):1150-5.

PMID: 25037626 DOI: 10.1007/s00120-014-3540-2.

References

Klimm B, Diehl V, Pfistner B, Engert A . Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl. 2005; (66):125-34. DOI: 10.1111/j.1600-0609.2005.00466.x. View

Eich H, Diehl V, Gorgen H, Pabst T, Markova J, Debus J . Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010; 28(27):4199-206. DOI: 10.1200/JCO.2010.29.8018. View

Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M . Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's.... J Clin Oncol. 2003; 21(19):3601-8. DOI: 10.1200/JCO.2003.03.023. View

Hillner B, Smith T, Desch C . Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000; 18(11):2327-40. DOI: 10.1200/JCO.2000.18.11.2327. View

Engert A, Franklin J, Eich H, Brillant C, Sehlen S, Cartoni C . Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007; 25(23):3495-502. DOI: 10.1200/JCO.2006.07.0482. View

Peterson E, Coombs L, DeLong E, Haan C, Ferguson T . Procedural volume as a marker of quality for CABG surgery. JAMA. 2004; 291(2):195-201. DOI: 10.1001/jama.291.2.195. View

Bender R, Grouven U . [Possibilities and limitations of statistical regression models for the calculation of threshold values for minimum provider volumes]. Z Arztl Fortbild Qualitatssich. 2006; 100(2):93-8. View

Terschuren C, Gierer S, Brillant C, Paulus U, Loffler M, Hoffmann W . Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?. Ann Oncol. 2010; 21(10):2045-2051. DOI: 10.1093/annonc/mdq214. View

Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D . Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348(24):2386-95. DOI: 10.1056/NEJMoa022473. View

10.

Lipscomb J . Transcending the volume-outcome relationship in cancer care. J Natl Cancer Inst. 2006; 98(3):151-4. DOI: 10.1093/jnci/djj055. View

11.

Engert A, Plutschow A, Eich H, Lohri A, Dorken B, Borchmann P . Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363(7):640-52. DOI: 10.1056/NEJMoa1000067. View

12.

Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O . Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002; 20(2):476-84. DOI: 10.1200/JCO.2002.20.2.476. View

13.

Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig W . The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int. 2010; 107(17):295-301. PMC: 2872821. DOI: 10.3238/arztebl.2010.0295. View

14.

Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A . Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12.... J Clin Oncol. 2011; 29(32):4234-42. DOI: 10.1200/JCO.2010.33.9549. View

15.

Grouven U, Kuchenhoff H, Schrader P, Bender R . Flexible regression models are useful tools to calculate and assess threshold values in the context of minimum provider volumes. J Clin Epidemiol. 2008; 61(11):1125-31. DOI: 10.1016/j.jclinepi.2007.11.020. View

16.

Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W, Lieb K . The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int. 2010; 107(16):279-85. PMC: 2868984. DOI: 10.3238/arztebl.2010.0279. View

17.

Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R . Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004; 15(2):276-82. DOI: 10.1093/annonc/mdh046. View

18.

Baumann W, Nonnenmacher A, Weiss B, Schmitz S . Patient satisfaction with care in office-based oncology practices. Dtsch Arztebl Int. 2009; 105(50):871-7. PMC: 2689630. DOI: 10.3238/arztebl.2008.0871. View

19.

Hollenbeck B, Dunn R, Miller D, Daignault S, Taub D, Wei J . Volume-based referral for cancer surgery: informing the debate. J Clin Oncol. 2006; 25(1):91-6. DOI: 10.1200/JCO.2006.07.2454. View

20.

Frassoni F, Labopin M, Powles R, Mary J, Arcese W, Bacigalupo A . Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000; 355(9213):1393-8. DOI: 10.1016/s0140-6736(00)02137-1. View